| Name | Title | Contact Details |
|---|
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.
Qualitest Pharmaceuticals is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Drawing inspiration from the pioneering women and community leaders who helped establish the Hospital in 1875, Lawrence General has remained focused throughout its history to serve the community as a private, not-for-profit acute care hospital. The Hospital’s physicians and caregivers offer treatment to all patients, regardless of race, color, creed, or national origin. Every member of the clinical team works to assure the quality and level of care the Hospital provides, supporting community education and research to improve the health of the Merrimack Valley and its citizens.
EZ-MED is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Higher Dimension Research is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.